Cube Pharmaceuticals announced that the company received the “Notice of Acceptance” for the registration and marketing license application for mesalazine enteric tablets issued by the State Drug Administration.
立方制药：美沙拉秦肠溶片药品注册上市许可申请获受理
Cube Pharmaceuticals: Mesalazine Enteric Tablet Drug Registration and Marketing License Application Accepted
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.